Figure 2.

Ultrasound-targeted microbubble destruction (UTMD) alleviates immunosuppression in the late-stage tumor. (A) Timeline of the treatment protocol and group setting. Twenty-one days after incubation, the tumor-bearing mice in the study group received ultrasound treatment. The control group received no treatment. (B) The pattern of microbubble injection. A low dose of microbubble was continuously injected throughout the whole process. The total injected volume of diluted microbubble was 0.24 ml for 600 s. Tumor size measurement and treatment utilization distribution. (C–E) Representative flow cytometry dot plots (left) and cumulative composite data (right) of the frequency of T cells, CD8⁺ T cells and CD4⁺ T cells, and CD71⁺ erythroid progenitor cells (CECs) in the spleen of Lewis lung cancer (LLC) tumor-bearing mice. Each point represents data from an individual mouse (n = 5). (F) The time-point distribution of multiple treatments and tumor measurements. (G) The curve line of tumor growth after ultrasound treatments (n = 8). There is no significant difference in tumor volume at the start point between the two groups. The tumor growth curve also showed no difference. **P < 0.01, NS, no significance.